The last time I wrote about Annexon (ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place". In this article ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...